12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vidaza azacitidine regulatory update

The U.K.'s NICE issued a second final appraisal determination (FAD) recommending Vidaza azacitidine after Celgene revised its existing patient access scheme to provide an additional undisclosed discount for the cancer drug. NICE said the additional discount produced an incremental cost effectiveness ratio (ICER) of £47,200 ($75,563)...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >